Stéphane Degove
Amministratore Delegato presso GamaMabs Pharma SA
Profilo
Stéphane Degove is the founder of Endotis Pharma SARL (founded in 2003) where he held the title of Chief Financial Officer and Atamyo Therapeutics SAS (founded in 2020) where he previously held the title of Chief Executive Officer & Director.
Mr. Degove's current job is Chairman at IDB Consulting SA. He previously worked at Sanofi SA as a Principal.
Mr. Degove received his undergraduate degree from ESCP Europe Campus Paris.
Mr. Degove is also the founder of GamaMabs Pharma SA.
Posizioni attive di Stéphane Degove
Società | Posizione | Inizio |
---|---|---|
GamaMabs Pharma SA
GamaMabs Pharma SA Medical/Nursing ServicesHealth Services GamaMabs Pharma SA specializes in developing monoclonal antibodies. It offers research and development solutions for biopharmaceutical industry. The company was founded by Jean-Francois Prost and Stephane Degove in June 2013 and is headquartered in Toulouse, France. | Amministratore Delegato | - |
IDB Consulting SA
IDB Consulting SA Information Technology ServicesTechnology Services IDB Consulting SA develops and markets information technology solutions. The company offers database management, application development, data warehousing, software support, and business intelligence services. Additionally, IDB Consulting provides outsourced accounting, budgeting, forecasting, and financial consulting services to startups and small private companies. The company partners with Oracle Corporation and IBM. Its clientele includes Everest Group, HSBC, PriceWaterHouse, Banc of America, and Meriwest Credit Union. The company was founded in 1995 and is headquartered in Paris, France | Presidente | 05/02/2020 |
Atamyo Therapeutics SAS
Atamyo Therapeutics SAS BiotechnologyHealth Technology Atamyo Therapeutics SAS is a clinical-stage biopharmaceutical company based in France. Atamyo leverages unique expertise in AAV-based gene therapy and muscular dystrophies from the Progressive Muscular Dystrophies Laboratory at Genethon, a spin-off of gene therapy pioneer Genethon. Atamyo's most advanced programs address different forms of limb-girdle muscular dystrophies (LGMD), with two clinical-stage programs targeting respectively LGMD-R9 and LGMD-R5. The name of the French company is derived from two words\: Celtic Atao which means "always" or "forever" and Myo which is the Greek root for muscle. Atamyo conveys the spirit of its commitment to improve the life of patients affected by neuromuscular diseases with life-long efficient treatments. Atamyo brings to patients with musculoskeletal diseases a new generation of gene therapies with enhanced safety and efficacy. The private company was founded in 2020 by Stéphane Degove and Isabelle Richard. Stéphane Degove has been the CEO since 2020. | Fondatore | 01/01/2020 |
Precedenti posizioni note di Stéphane Degove
Società | Posizione | Fine |
---|---|---|
Endotis Pharma SARL
Endotis Pharma SARL Pharmaceuticals: MajorHealth Technology Endotis Pharma SARL is a holding company, which is engaged in the development of differentiated cardiovascular therapeutics based on validated targets and modes of action. The company was founded in 2003 and it is headquartered in Romainville, France. | Fondatore | - |
Sanofi SA | Corporate Officer/Principal | - |
Formazione di Stéphane Degove
ESCP Europe Campus Paris | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Aziende private | 5 |
---|---|
Endotis Pharma SARL
Endotis Pharma SARL Pharmaceuticals: MajorHealth Technology Endotis Pharma SARL is a holding company, which is engaged in the development of differentiated cardiovascular therapeutics based on validated targets and modes of action. The company was founded in 2003 and it is headquartered in Romainville, France. | Health Technology |
GamaMabs Pharma SA
GamaMabs Pharma SA Medical/Nursing ServicesHealth Services GamaMabs Pharma SA specializes in developing monoclonal antibodies. It offers research and development solutions for biopharmaceutical industry. The company was founded by Jean-Francois Prost and Stephane Degove in June 2013 and is headquartered in Toulouse, France. | Health Services |
Sanofi SA | Health Technology |
IDB Consulting SA
IDB Consulting SA Information Technology ServicesTechnology Services IDB Consulting SA develops and markets information technology solutions. The company offers database management, application development, data warehousing, software support, and business intelligence services. Additionally, IDB Consulting provides outsourced accounting, budgeting, forecasting, and financial consulting services to startups and small private companies. The company partners with Oracle Corporation and IBM. Its clientele includes Everest Group, HSBC, PriceWaterHouse, Banc of America, and Meriwest Credit Union. The company was founded in 1995 and is headquartered in Paris, France | Technology Services |
Atamyo Therapeutics SAS
Atamyo Therapeutics SAS BiotechnologyHealth Technology Atamyo Therapeutics SAS is a clinical-stage biopharmaceutical company based in France. Atamyo leverages unique expertise in AAV-based gene therapy and muscular dystrophies from the Progressive Muscular Dystrophies Laboratory at Genethon, a spin-off of gene therapy pioneer Genethon. Atamyo's most advanced programs address different forms of limb-girdle muscular dystrophies (LGMD), with two clinical-stage programs targeting respectively LGMD-R9 and LGMD-R5. The name of the French company is derived from two words\: Celtic Atao which means "always" or "forever" and Myo which is the Greek root for muscle. Atamyo conveys the spirit of its commitment to improve the life of patients affected by neuromuscular diseases with life-long efficient treatments. Atamyo brings to patients with musculoskeletal diseases a new generation of gene therapies with enhanced safety and efficacy. The private company was founded in 2020 by Stéphane Degove and Isabelle Richard. Stéphane Degove has been the CEO since 2020. | Health Technology |
- Borsa valori
- Insiders
- Stéphane Degove